Roche's SMA drug risdiplam hits targets in children ahead of...

It’s not far off crunch time for Roche’s potential spinal muscular atrophy (SMA) drug, risdiplam, which the big Swiss pharma hopes will generate blockbuster revenues as well as taking marke

Roche fights off biosimilar competition as new medicines' sa...

Roche has seen its pharmaceutical sales increase in 2019 as it fought off the impact of cheaper near-copies of its most successful drugs with a batch of new medicines.

Roche files Tecentriq, Avastin combo as a liver cancer thera...

Pfizer launches biosimilars to Roche's 'big three' cancer dr...

Pfizer has announced the launch of its competitors to Roche’s ‘big three’ cancer drugs in the US, at a “substantially discounted price” compared with the originators.

Roche edges closer to SMA market as risdiplam hits target in...

Roche is to begin discussions with regulators about new data from risdiplam, its developmental oral treatment for the rare muscle wasting disease spinal muscular atrophy (SMA) after support

Tumour-agnostic drugs ‘game-changing’, says NICE as it rejec...